Last Updated : April 24, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area Sort descending | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Mayzent | siponimod | Secondary progressive multiple sclerosis | Reimburse with clinical criteria and/or conditions | Complete | ||
Epidiolex | cannabidiol | Seizures associated with Tuberous Sclerosis Complex (TSC) | Active | |||
Zemaira | Alpha1-proteinase inhibitor (Human) | Severe Alpha1-proteinase inhibitor deficiency | Reimburse with clinical criteria and/or conditions | Complete | ||
N/A | eltrombopag | Severe Aplastic Anemia (SAA) | Reimburse with clinical criteria and/or conditions | Active | ||
Nucala | mepolizumab | Severe chronic rhinosinusitis with nasal polyps | Reimburse with clinical criteria and/or conditions | Complete | ||
Baqsimi | glucagon | Severe hypoglycemic reactions | Reimburse with clinical criteria and/or conditions | Complete | ||
Increlex | mecasermin | Severe primary insulin-like growth factor-1 deficiency | Reimburse with clinical criteria and/or conditions | Complete | ||
Verkazia | cyclosporine | Severe vernal keratoconjunctivitis, pediatric (≥4 years) | Reimburse with clinical criteria and/or conditions | Complete | ||
Revestive | Teduglutide | Short bowel syndrome | Reimburse with clinical criteria and/or conditions | Complete | ||
Revestive | teduglutide | Short Bowel Syndrome (SBS), pediatrics | Reimburse with clinical criteria and/or conditions | Complete |